{"id":"intravenous-esomeprazole","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal pain"},{"rate":null,"effect":"Hypomagnesemia (with long-term use)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Esomeprazole is the active S-enantiomer of omeprazole, a proton pump inhibitor (PPI). It irreversibly binds to and inhibits the H+/K+-ATPase enzyme on the secretory surface of gastric parietal cells, thereby suppressing both basal and stimulated gastric acid production. The intravenous formulation provides rapid onset of action for acute acid-related conditions.","oneSentence":"Intravenous esomeprazole inhibits gastric acid secretion by blocking the proton pump in parietal cells of the stomach.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:49.142Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acute gastroesophageal reflux disease (GERD)"},{"name":"Peptic ulcer disease"},{"name":"Stress ulcer prophylaxis in critically ill patients"},{"name":"Zollinger-Ellison syndrome"}]},"trialDetails":[{"nctId":"NCT07312370","phase":"PHASE4","title":"Esomeprazole Plus Sucralfate for Post-ESD Ulcer Healing","status":"NOT_YET_RECRUITING","sponsor":"LanZhou University","startDate":"2026-04-20","conditions":"Early Gastric Cancer, Gastric Dysplasia, Gastric Neoplasms","enrollment":120},{"nctId":"NCT05582174","phase":"PHASE4","title":"PPI Infusion Versus Oral Acid Pump Inhibitors for Bleeding Peptic Ulcers","status":"RECRUITING","sponsor":"Chinese University of Hong Kong","startDate":"2023-05-18","conditions":"Upper GI Bleeding, Proton Pump Inhibitors","enrollment":594},{"nctId":"NCT07399054","phase":"","title":"Efficacy and Safety of Esomeprazole 40 mg IV in Post-Surgical Patients Admitted to the ICU","status":"NOT_YET_RECRUITING","sponsor":"Asian Institute of Gastroenterology, India","startDate":"2026-01-15","conditions":"Stress Ulcers, Reflux Episodes","enrollment":50},{"nctId":"NCT07248722","phase":"NA","title":"Acid-suppression Drugs After Prophylactic Endoscopic Variceal Treatment of Esophagogastric Variceal Bleeding in Cirrhosis","status":"NOT_YET_RECRUITING","sponsor":"General Hospital of Shenyang Military Region","startDate":"2025-12","conditions":"Esophageal and Gastric Varices, Liver Cirrhosis","enrollment":210},{"nctId":"NCT06561542","phase":"PHASE1","title":"A Phase I Study of LX22001 for Injection in Healthy Subjects","status":"RECRUITING","sponsor":"Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.","startDate":"2024-08-05","conditions":"Healthy","enrollment":70},{"nctId":"NCT03452865","phase":"PHASE3","title":"Esomeprazole to Reduce Organ Failure in Sepsis","status":"COMPLETED","sponsor":"Università Vita-Salute San Raffaele","startDate":"2020-01-28","conditions":"Sepsis, Septic Shock","enrollment":300},{"nctId":"NCT05624229","phase":"PHASE4","title":"Efficacy of Proton Pump Inhibitors in Cirrhotic Patients With Acute Variceal Bleeding","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2023-10-01","conditions":"Upper Gastrointestinal Hemorrhage","enrollment":672},{"nctId":"NCT02197039","phase":"","title":"The Selection Criteria for the Second-look Endoscopy Among Patients With Bleeding Peptic Ulcers","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2011-08","conditions":"Peptic Ulcer Hemorrhage","enrollment":316},{"nctId":"NCT05061563","phase":"PHASE1","title":"A Study to Learn How a Proton Pump Inhibitor Affects the Way Elinzanetant (BAY 3427080) Moves Into, Through and Out of the Body, and How Much of it Gets Absorbed by the Body When Taken as a Single and Small Radioactive Dose in Healthy Adults","status":"COMPLETED","sponsor":"Bayer","startDate":"2021-09-30","conditions":"Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men, Hot Flashes","enrollment":14},{"nctId":"NCT02456012","phase":"PHASE4","title":"Long-term Oral Esomeprazole for Prevention of Peptic Ulcer Rebleeding in High-risk Patients","status":"COMPLETED","sponsor":"Hsiu-Chi Cheng","startDate":"2015-04","conditions":"Peptic Ulcer Hemorrhage","enrollment":268},{"nctId":"NCT04432233","phase":"PHASE4","title":"Intravenous Triple Therapy in the Treatment of Helicobacter Pylori Infection and Related Complications Caused by Active Peptic Ulcer Disease","status":"UNKNOWN","sponsor":"Shanghai Jiao Tong University School of Medicine","startDate":"2020-06-15","conditions":"Helicobacter Pylori Infection, Intravenous Drug Usage","enrollment":60},{"nctId":"NCT01579539","phase":"PHASE3","title":"The Effect of Intravenous Glucocorticoids on the Tearfilm in Eyes With Thyroid-associated Ophthalmopathy","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2013-06-27","conditions":"Thyroid-associated Ophthalmopathy, Dry Eye Syndrome","enrollment":18},{"nctId":"NCT01123031","phase":"PHASE4","title":"Oral vs Intravenous and Proton Pump Inhibitor (PPI）for Peptic Ulcer Bleeding (PUB)","status":"WITHDRAWN","sponsor":"Changhua Christian Hospital","startDate":"2010-04","conditions":"Upper Gastrointestinal Bleeding","enrollment":""},{"nctId":"NCT01822600","phase":"PHASE4","title":"The Therapeutic Role of Intravenous Albumin Administration for Peptic Ulcer Bleeding Patients With Hypoalbuminemia","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2010-01","conditions":"Peptic Ulcer Bleeding, Hypoalbuminemia","enrollment":91},{"nctId":"NCT02479581","phase":"PHASE2","title":"The Safety and Efficacy of the Enhanced Recovery After Surgery(ERAS)Applied on Cardiac Surgery With Cardiopulmonary Bypass","status":"COMPLETED","sponsor":"Xiangya Hospital of Central South University","startDate":"2015-07","conditions":"Valvular Heart Disease","enrollment":226},{"nctId":"NCT02157376","phase":"PHASE3","title":"Stress Ulcer Prophylaxis of Intravenous Esomeprazole in Chinese Seriously Ill Patients","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-07","conditions":"Stress Ulcer Prophylaxis","enrollment":343},{"nctId":"NCT02205489","phase":"PHASE4","title":"Management Of The Infusion-Associated Reactions In RRMS Patients Treated With LEMTRADA","status":"COMPLETED","sponsor":"Genzyme, a Sanofi Company","startDate":"2014-10","conditions":"Relapsing-remitting Multiple Sclerosis","enrollment":58},{"nctId":"NCT01591083","phase":"PHASE4","title":"The Efficacy of Double Doses of Oral Esomeprazole in Preventing Rebleeding for Patients With Bleeding Peptic Ulcers","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2011-08","conditions":"Peptic Ulcer Bleeding","enrollment":474},{"nctId":"NCT01142245","phase":"PHASE3","title":"Effect of IV and Oral Esomeprazole in Prevention of Recurrent Bleeding From Peptic Ulcers After Endoscopic Therapy","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2008-01","conditions":"Peptic Ulcer, Bleeding","enrollment":263},{"nctId":"NCT02444507","phase":"PHASE4","title":"A Pharmacokinetic Study to Evaluate the Bioequivalence of a Test Formulation Compared to an Equivalent Dose of a Reference Drug Product","status":"UNKNOWN","sponsor":"isRed Pharma & Biotech Research Corporation","startDate":"2015-04","conditions":"Healthy Adult Subjects","enrollment":14},{"nctId":"NCT00881413","phase":"PHASE4","title":"Esomeprazole Versus Pantoprazole to Prevent Peptic Ulcer Rebleeding","status":"WITHDRAWN","sponsor":"Lotung Poh-Ai Hospital","startDate":"","conditions":"Peptic Ulcer","enrollment":""},{"nctId":"NCT01069081","phase":"PHASE2","title":"Docetaxel and Cisplatin Chemotherapy With or Without High Dose Proton Pump Inhibitor in Metastatic Breast Cancer","status":"COMPLETED","sponsor":"Fudan University","startDate":"2009-08","conditions":"Breast Cancer, Metastasis, Neoplasm","enrollment":94},{"nctId":"NCT01783899","phase":"NA","title":"Clinical Evaluation of Hemospray in Hemostasis of Active Variceal Bleeding","status":"COMPLETED","sponsor":"Theodor Bilharz Research Institute","startDate":"2013-01","conditions":"Variceal Hemorrhage","enrollment":30},{"nctId":"NCT02197143","phase":"PHASE4","title":"A Comparison of Efficacy of Intravenous Esomeprazole and Ranitidine Treatment of Dyspeptic Pain","status":"COMPLETED","sponsor":"Pamukkale University","startDate":"2013-03","conditions":"Dyspepsia","enrollment":286},{"nctId":"NCT00633035","phase":"PHASE4","title":"Comparison of Esomeprazole and Famotidine for Stress Ulcer Prophylaxis in Neurosurgical Intensive Care Unit","status":"COMPLETED","sponsor":"Far Eastern Memorial Hospital","startDate":"2007-09","conditions":"Ulcer","enrollment":60},{"nctId":"NCT00230516","phase":"PHASE4","title":"Study of 24-hour Intragastric pH Profiles of Esomeprazole 40 mg and Lansoprazole 30 mg in Healthy Volunteer Subjects","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2005-09","conditions":"Healthy","enrollment":100},{"nctId":"NCT00164788","phase":"PHASE2","title":"A Comparison of Gastric pH Control With High Dose Intravenous or Oral Esomeprazole","status":"TERMINATED","sponsor":"Chinese University of Hong Kong","startDate":"2004-07","conditions":"Gastrointestinal Hemorrhage","enrollment":7},{"nctId":"NCT00629564","phase":"PHASE4","title":"An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-09","conditions":"GERD","enrollment":60},{"nctId":"NCT00635414","phase":"PHASE4","title":"Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-08","conditions":"GERD","enrollment":60},{"nctId":"NCT00626262","phase":"PHASE4","title":"Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-07","conditions":"Gastroesophageal Reflux Disease","enrollment":60},{"nctId":"NCT00625495","phase":"PHASE4","title":"Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2002-09","conditions":"Gastroesophageal Reflux Disease","enrollment":60},{"nctId":"NCT00206050","phase":"PHASE4","title":"Study of Intragastric pH Profile After 5 Days Pantoprazole 40 mg iv Followed by Oral Esomeprazole 40 mg po or Oral Pantoprazole 40 mg po","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2004-09","conditions":"Healthy","enrollment":40},{"nctId":"NCT00474019","phase":"PHASE1","title":"Phase 1 Pharmacokinetics of Intravenous Nexium in Children","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2007-10","conditions":"Pharmacokinetics","enrollment":42},{"nctId":"NCT00590928","phase":"PHASE4","title":"Gastric pH in Critically Ill Patients","status":"COMPLETED","sponsor":"Medical University of Vienna","startDate":"2004-07","conditions":"Critically Ill Patients, Indication for Stress Ulcer Prophylaxis","enrollment":75},{"nctId":"NCT00471029","phase":"PHASE4","title":"Compare Efficacy of Gastric Acid Suppression by Oral and Intravenous Administration of Esomeprazole in Patients With Peptic Ulcer","status":"UNKNOWN","sponsor":"Pamela Youde Nethersole Eastern Hospital","startDate":"2005-09","conditions":"Peptic Ulcer","enrollment":20}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":37,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["IV","nexium"],"phase":"phase_3","status":"active","brandName":"Intravenous Esomeprazole","genericName":"Intravenous Esomeprazole","companyName":"Chinese University of Hong Kong","companyId":"chinese-university-of-hong-kong","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Intravenous esomeprazole inhibits gastric acid secretion by blocking the proton pump in parietal cells of the stomach. Used for Acute gastroesophageal reflux disease (GERD), Peptic ulcer disease, Stress ulcer prophylaxis in critically ill patients.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}